Diffuse Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma: Genetic Classification and Its Implications for Prognosis and Treatment

Hematol Oncol Clin North Am. 2019 Aug;33(4):575-585. doi: 10.1016/j.hoc.2019.03.001. Epub 2019 May 18.


Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma, is characterized by both clinical and molecular heterogeneity. Despite efforts to tailor therapy for individual patients, treatment remains uniform and a subset of patients have poor outcomes. The past decade has witnessed a dramatic expansion of our understanding of the genomic underpinnings of this disease, especially with the application of next-generation sequencing. In this review, the authors highlight the current genomic landscape of DLBCL and how this information provides a potential molecular framework for precision medicine-based strategies in this disease.

Keywords: Cell of origin; DLBCL; Diffuse large B-cell lymphoma; Genomic classifications; Precision medicine; Targeted therapy.

Publication types

  • Review

MeSH terms

  • Gene Expression Profiling / methods*
  • Gene Expression Regulation, Neoplastic
  • Genetic Heterogeneity
  • Genetic Testing
  • High-Throughput Nucleotide Sequencing
  • Humans
  • Lymphoma, Large B-Cell, Diffuse / classification*
  • Lymphoma, Large B-Cell, Diffuse / genetics*
  • Lymphoma, Large B-Cell, Diffuse / pathology
  • Lymphoma, Large B-Cell, Diffuse / therapy
  • Molecular Targeted Therapy
  • Multigene Family
  • Precision Medicine